Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
April 10, 2006
- BUSINESS NEWS IN BRIEF
April 10, 2006
- JMA
April 10, 2006
- FY2006 Budget Proposal Approved
April 10, 2006
- 39 of World's 99 Top-Selling Drugs Unapproved in Japan: Mr Wolf of PhRMA
April 10, 2006
- Korosho to Gear Up Steps to Eliminate Provisional Delivery
April 10, 2006
- Economist Conferences: 5th Roundtable on Healthcare Reform in Japan
April 10, 2006
- REGULATORY NEWS IN BRIEF
April 10, 2006
- Daiichi Sankyo Selects 5 Top-Priority Projects
April 10, 2006
- Ono, Medarex in Collaboration to Develop Antibody Therapeutics
April 10, 2006
- R&D NEWS IN BRIEF
April 10, 2006
- TeGenero's Investigational Antibody Drug Causes Disaster in PI Trial
April 3, 2006
- The WHO, IFPMA to Cooperate to Combat Counterfeit Drugs
April 3, 2006
- Korosho to Standardize Package Inserts for Generics
April 3, 2006
- REGULATORY NEWS IN BRIEF
April 3, 2006
- Shift to Low-priced Drugs Could Weaken Wholesalers: FJPWA
April 3, 2006
- SELF-MEDICATION NEWS IN BRIEF
April 3, 2006
- HUMAN RESOURCES NEWS IN BRIEF
April 3, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 3, 2006
- STATISTICS
April 3, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…